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doi:10.1016/j.kjms.2011.10.023Abstract Isocitrate dehydrogenase (IDH) encodes a nicotinamide adenine dinucleotide
phosphateþ-dependent enzyme for oxidative decarboxylation of isocitrate and has an essential
role in the tricarboxylic acid cycle.Mutations of IDH1 and IDH2have been identified in patientswith
glioma, leukemia, and other cancers. However, the incidence of IDH mutations in acute myeloid
leukemia inTaiwan ismuch lowerthanthat reported inWesterncountries.Thereasonforthediffer-
ence is unknown and its clinical implications remain unclear. Acute lymphoblastic leukemia (ALL) is
a heterogenous hematopoietic malignancy. Oral squamous cell carcinoma (OSCC) results from
chronic carcinogen exposures and is highly prevalent in trucking workers, especially in southern
Taiwan. Subtypes of both diseases require specific treatments, and molecular markers for devel-
oping tailored treatments are limited. High-resolution melting (HRM) analysis is now a widely
used methodology for rapid, accurate, and low-cost mutation scanning. In this study, 90 adults
with OSC and 31 children with ALL were scanned by HRM analysis for IDH1 and IDH2 mutation hot
spots. In ALL, the allele frequency was 3.23% in both IDH1 and IDH2. In OSCC, the allele frequency
was 2.22% in IDH2. A synonymous mutation over pG313 (c.939A > G) of IDH2 was found in both
pediatric ALL and adult OSCC. Therefore, we concluded that mutations of IDH are uncommon in
ALL and OSCC and are apparently not a major consideration when selecting treatment modalities.
Copyrightª 2012, Elsevier Taiwan LLC. All rights reserved.of Laboratory Medicine, Kaohsiung Medical University Hospital, 100 Shih-Chuan 1st Road, Kaohsiung,
.org.tw (J.-G. Chang).
vier Taiwan LLC. All rights reserved.
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[11e15] and IDH2 mutations [13,16,21].Isocitrate dehydrogenase (IDH) encodes a nicotinamide
adenine dinucleotide phosphate (NADP)þ-dependent
enzyme for oxidative decarboxylation of isocitrate and
produces 2-oxoglutarate and carbon dioxide in the tricar-
boxylic acid cycle. The recent discovery of somatic hetero-
zygousmutations of IDH in glioblastoma is considered amajor
advance in oncology [1,2]. Mutations of IDH impair the ability
to catalyze the conversion of isocitrate to ɑ-ketoglutarate
(ɑ-KG), which decreases conversion of ɑ-KG to the metabo-
lite D2-hydroxyglutarate. Of the three IDH isoforms (IDH1,
IDH2, and IDH3), two isoforms (IDH1 and IDH2) are associated
with brain tumors [3e10], acute myeloid leukemia (AML)
[11e15], myelodysplastic syndromes [16,17], prostate
cancer [9], acute lymphoblastic leukemia (ALL) B [9], para-
ganglioma [18], thyroid cancer [19], and colorectal cancer
[3,20]. Like tumor suppressors, heterozygous missense
mutations of IDH1 residues act in a dominant negative
fashion [18].
Most studies agree thatmutational status in IDH1 and IDH2
is associated with poorer prognosis [11,21,22], while some
studies report no correlations [12,23]. In low-grade glioma,
however, IDH has a higher incidence of mutations [5,24],
i.e., 68% in diffuse astrocytoma, 69% in oligodendroglioma,
and 78% in oligoastrocytoma [24]. Grade IV secondary glio-
blastoma (GBM) also has a high incidence of IDH mutations
(88%). Some evidence indicates that the IDH mutation is an
early indicator of oncogenesis in secondary GBM [2].
Invasive oral squamous cell carcinoma (OSCC) accounts
for most malignant disorders of the oral cavity. Histologic
grading has limited value for predicting treatment
outcomes. Despite recent advances in surgical, radio-
therapy, and chemotherapy treatment protocols, the long-
term survival of patients with OSCC has not substantially
improved, and responses to different treatment modalities
are difficult to predict [25]. Since OSCC apparently
develops during several steps in the process of carcino-
genesis after chronic carcinogen exposure, tailored treat-
ments based on specific markers are needed [25,26]. Since
many molecular markers have already been proposed e.g.,
p53, epidermal growth factor receptor, c-erbB2, c-Jun,
Ki67, telomerase, cyclooxygenase-1 and -2, vascular endo-
thelial growth factor, [26,27], this study investigated
whether IDH has a role in the development of OSCC.
AML is a hematopoietic malignancy characterized by
failure of the myeloid precursors to mature. Because AML is
a heterogeneous disease, special therapeutic considerations
are needed for its varied phenotypes. In addition
to morphology and karyotype, World Health Organization
classifications of molecular markers, such as genetic muta-
tions of nucleophosmin, FMS-related tyrosine kinase, and
CCAAT/enhancer-binding protein alpha, must be considered
when selecting treatment strategies. ALL is also a heterog-
enous disease comprising multiple subtypes with different
genetic alterations and varied treatment responses [28].
Whole genome sequencing performed in searches for
new molecular markers of AML have revealed arginine
(R132) mutations in IDH1 [29,30]. A study of patients who
have AML with a normal cytogenic status found that 16%
had mutated IDH1 [30]. Studies by different researchgroups have also confirmed significant recurrence in IDH1
However, a recent National Taiwan University Hospital
(NTUH) study of 493 patients with AML revealed amuch lower
(5.5%) incidence of IDH mutation [31]. Although a possible
explanation for this low occurrence rate may be the differ-
ences in species between Western and Eastern countries, the
sensitivity of the current detection method is insufficient to
confirm this theory. This study compared the clinical and
biological features of IDH mutations in AML and in other
cancers (i.e., oral cancer) that are highly prevalent in betel
nut users in southern Taiwan. The IDH1 and IDH2mutations of
ALL and oral cancer were analyzed in patients treated in
Kaohsiung Medical University Hospital (KMUH). Additionally,
samples from four patients with AML were analyzed to
compare the difference between the KMUHandNTUH groups.
ALL is another form of leukemia associated with high
rates of immature lymphocytes. In southern Taiwan, oral
cancer is common in construction workers and truck drivers
who habitually chew betel nut. Instead of the direct
sequencing method used to detect mutations in the NTUH
study [31], this study applied high resolution melting (HRM)
analysis, which has proven highly effective for detecting
mutations [32,33], polymorphisms, and epigenetic differ-
ences [34], and it is rapidly becoming the standard muta-
tion scanning methodology. The polymerase chain reaction
(PCR) amplification and analysis were performed in a well
by closed-tube method [32,33]. The values obtained by
real-time PCR (LightCycler 480, Roche Applied Science,
USA) in the HRM analysis were evaluated for use in identi-
fying hot spots of IDH1 and IDH2 gene mutations.
Methods
Patients
Ninety patients who were recently diagnosed with oral
cancer at Kaohsiung Medical University Hospital and Chan-
ghua Christian Hospital were recruited. Mononuclear cells
were obtained from four pediatric patients with AML and 35
with ALL in accordance with protocols approved by the
Institutional Review Boards of the Kaohsiung Medical
University and Changhua Christian Hospital. Of the 35
pediatric patients with ALL, four were excluded from the
final statistical analysis due to insufficient DNA to complete
both the IDH1 and IDH2 surveys.
Mononuclear cell samples from AML and ALL patients
were centrifuged and stored at 80C before use. Biopsy
samples were obtained from the oral cancer patients during
surgery and before systemic treatment or radiotherapy
using a protocol approved by the Institutional Review Board
at Kaohsiung Medical University. All tissue specimens were
classified histopathologically as squamous cell carcinoma
and stored immediately after resection in liquid nitrogen
before DNA extraction.
Design and synthesis of PCR primers
The genomic region spanning the wild-type V71, G97, G123,
and R132 of IDH1 at Exon 4 was amplified by PCR with sense
140 J.-Y. Tang et al.and antisense primers 50-AACGACCAAGTCACCAAGGA, and 50-
GCCAACATGACTTACTTGATCC, respectively. Exon 4 and Exon
7 of IDH2, where a single nucleotide polymorphism (SNP) is
normally found at R140, R172, and V294, were amplified by
upstream primers of 50-GGGGTTCAAATTCTGGTTGA and
50-GTCAGCCTTCTGCCCTCTC and downstream primers of
50-CAGTGGATCCCCTCTCCAC and 50-TCCAGCCAGAGAAGAC
CAAC, respectively.
DNA extraction
Blood DNA was extracted by first drawing 8 mL of blood into
a Vacutainer with ethylene diamine tetra-acetic acid anti-
coagulant. After mixing with red cell lysis buffer (1 mM
NH4HCO3, 115 mM NH4Cl), cell pellets were collected by
centrifuge at 4C. The cell pellets were resuspended in
white cell lysis buffer (100 mM Tris-Cl pH 7.6, 40 mM EDTA
pH 8, 50 mM NaCl, 0.2% SDS (sodium dodecyl sulfate), 0.05%
sodium azide). Protein precipitate solution (w6 M NaCl)
was added and spun to collect supernatant. The superna-
tant was then mixed with 100% isopropanol and centri-
fuged. The DNA was obtained by resuspending the pellet in
TE buffer.
Fresh tumor tissues were frozen and stored in liquid
nitrogen before analysis. The DNA was collected by first
washing 60e80 mg of tissue with PBS (phosphate buffered
saline). The dissected tissue was resuspended in DNA buffer
(1 M Tris pH 8.0, 0.5 M EDTA) and incubated overnight with
proteinase K (10 mg/ml) and 10% SDS at 45C overnight. The
DNA was purified using standard procedures for phenol
extraction and ethanol precipitation as described previ-
ously [35].
HRM analysis
The IDH1 and IDH2 mutations were identified by HRM
analysis as described previously [32,33,36]. The LightCycler
480 High Resolution Melting Master kit (Reference
04909631001, Roche Diagnostics, USA) was used according
to manufacturer instructions, and LightCycler 480 Gene-
Scanning Software version 1.0 (Roche Diagnostics) was
used for all data analysis. The PCR reactions were per-
formed in duplicate in 20 ml final volume using the Light-
Cycler 480 High-Resolution Melting Master 1X buffer,
containing Taq polymerase, nucleotides, ResoLight dye,
and 30 ng DNA. For detecting IDH mutations, primers and
MgCl2 were used at a concentration of 0.25 mmol/l and
2.5 mmol/l.
A SYBR green I filter (533 nm) was used in the PCR
program, which included an initial denaturatione
activation step at 95C for 10 minutes and then 45 cycles
of the following program: denaturation at 95C for 15
seconds, annealing at 60C for 15 seconds and extension at
72C for 15 seconds, fluorescence detection in single
acquisition mode. The melting program included three
steps: (1) denaturization at 95C for 1 minute, (2) rena-
turization at 40C for 1 minute, and (3) subsequent
melting by continuous fluorescent reading from 60 to 90C
at a rate of 25 acquisitions/C. The curve shape and peak
height in each curve were checked to confirm good
reproducibility.Direct sequencing
After identifying SNPs based on HRM analysis and normalized
and temperature-shifted melting curves, the samples were
subjected to direct sequencing using the sense and
antisense primers as described previously [32,33,35].
Sequencing was performed in the ABI Prism 310 Genetic
Analyzer (Applied Biosystems, USA) according to the manu-
facturer instructions. After HRM analysis, the samples were
purified with PCR-MTM for system clean up (VIOGEN, Sunny-
vale, CA USA) and then directly sequenced. The sequence
reaction was performed in a final volume of 10 ml, including
1 ml of the purified PCR product, 2.5 mmol/l of one of the PCR
primers, 2 ml of ABI PRISM terminator cycle sequencing kit
version 3.1 (Applied Biosystems, USA) and 2 ml 5X sequence
buffer. The sequencing programme started from 96C for
1 minute and was followed by 25 cycles of the following
PCR program: denaturization at 96C for 10 seconds,
annealing at 50C for 5 seconds, and extension at 60C for 4
minutes.Results
This study recruited 90 adults with OSCC and 31 pediatric
patients with ALL. Four pediatric with AML were also
analyzed. The primers were designed to provide sufficient
specificity within a range of sequences in which four IDH1
mutation hot spots (V71, G97, G123, andR132) and three
IDH2 (R140, R172, and V294) have been reported (Fig. 3).
The mutational screening included one IDH1 exon and two
IDH2 exons, which included 866 codons. Normalized
temperature-shifted data were clearly differentiated
between the mutation and normal samples.
Four heterozygous changes were found in ALL samples.
One (s.22) resided in bp 315 at Exon 4 of IDH1. Fig. 1A
(upper panel) shows the melting profile of s.22. A single
nucleotide polymorphism of C > T was confirmed by direct
sequencing (Fig. 1A, lower panel). No mutations were found
in Exon 4 of IDH2 after direct sequencing of the suspected
s.35 (Fig. 1B, left panel). Two ALL (s.18, s.21) and two AML
specimens (s.34, s.37) specimens showed heterozygous
changes in Exon 7 of IDH2 (Fig. 1B, right panel). Direct
sequencing confirmed the occurrence of the same SNP at bp
(base pair) 939 (Fig. 1C). Although one base substitution
was noted, the same protein was encoded, which indicated
a synonymous mutation. The estimated allele frequency of
ALL was 3.23% in both IDH1 and IDH2 (two of 62).
Finally, 90 oral cancer squamous cell carcinomas were
screened. Fig. 2 shows the normalized and temperature
shifted difference plots. No mutations were found within
Exon 4 in either IDH1 (Fig. 2A) or IDH2 (Fig. 2B). No nucle-
otide polymorphism was found in o.12 after direct
sequencing (sequence chromatogram not shown). In Exon 7
of IDH2, the melting curve showed differences in normal-
ized temperature-shifted data between mutation and
normal samples. The c.21, a previously recognized single
nucleotide polymorphism in ALL, was used as a positive
control and mixed with OSCC samples for analysis. The o.11
and o.128 showed similarly shifted curves (Fig. 2C). They
harbored the same SNP (A > G) at codon 313, which indi-
cated a synonymous change. After sequencing, comparison
Figure 1. Detection of SNP in ALL and AML by HRM analysis and confirmation by direct sequencing. Normalized and temperature
shifted difference plots for IDH1 and IDH2 genes. A. Mutation screening over exon4 of IDH1. The DNA samples of leukemia carrying
heterozygous variation were distinguished after grouping of different melting curves by shapes (arrowhead: wild-type and
heterozygous). Direct sequencing over the range of codons of interests revealed a rapid base change in bp 315 from Cytosine to
Thymine. B. Left panel: Mutation screening over exon4 of IDH2. After obtaining the melting profile of s.35, direct sequencing
revealed no mutation. Right panel: Mutation screening over exon7 of IDH2. The melting profiles for s.18, s.21, s.34 and s.37 clearly
distinguished A > G. C. Representative sequencing chromatograms of wild-type (left panel) and IDH2 mutations (right panel)
spanning the codon 939. Nucleotide variation from Adenine to Guanine is visible (arrowhead).
IDH HRM analysis 141of melting profiles of o.123 and o.84 revealed no mutations.
The estimated allele frequency was 2.22% (two of 180).
Compared with data reported in the literature, the
number of allele changes observed in this survey was lower
than those reported in earlier studies. However, allele
change in pG313 might be seen as a novel finding (Fig. 3).
Possible explanations are differences in tumour genetics
and the different age range of the population. Another
possibility is that the IDH mutations of interest were beyond
the range of hotspots investigated in this study.Discussion
The importance of mutation screening increases as treat-
ment options become available for cancers that have
different phenotypes but similar pathology. The main
concerns when selecting mutation detection techniques are
cost, mutation type, sample source, detection sensitivity,
detection specificity, and template quality. Some
sequencing methods detect mutations by identifying indi-
vidual nucleotides with stands that are complementary
Figure 2. Detection of SNP in oral cancer by HRM analysis and confirmation by direct sequencing. Normalized and temperature
shifted difference plots for IDH1 and IDH2 genes. Panel A, direct sequencing of exon 4 of IDH1 showing no mutations. Panel B,
further direct sequencing of suspected heterozygous melting profile of o.12 showing no mutations. However, no mutation was
found. Panel C, HRM screening of o.11 and o.128 and c.21 from a previous ALL specimen showing heterozygous curve pattern
apparently harboring the same nucleotide polymorphism. Direct sequencing revealed no nucleotides mutations in o.123 and o.84.
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Figure 3. IDH mutation hot spots. Blue triangles indicate
reported mutations at specific residues. Red triangles indicate
SNPs discovered in this study.
IDH HRM analysis 143strand to the DNA sample. Such methods include direct
sequencing [37], pyrosequencing [38], nested sequencing
[39], mutant-enriched sequencing [40], cold sequencing
[41], and HRM analysis. Although direct sequencing is
currently considered the gold standard for detecting DNA
mutations, its drawbacks are its high cost and the need for
high-quality templates. Prescreening can minimize the
need for downstream sequencing. HRM analysis, however, is
relatively fast and cost-effective for both gene scanning
and SNP detection. This robust and highly sensitive method
is currently the preferred method of mutation detection in
most diagnostic laboratories [42]. However, inconsistent
quantities of DNA inputs can cause curve deviation and
false positive results [32]. Poor sample amplification can
also produce aberrant melting curves [32]. Therefore,
direct sequencing is recommended for additional confir-
mation of melting curves.
This study revealed similar single nucleotide poly-
morphisms in pG313 (c.939A > G) and pG105 (c.315C > T).
The latter is also found in adult patients with AML [43] and
in pediatric patients with Wilms tumor [44]. This observa-
tion confirms that HRM is a useful technique in clinical
settings. However, no amino acid mutation occurs in this
context since both the GGA and GGG codon polymorphism
are indicators of glycine translation, which is considered
a synonymous change. Therefore, the clinical relevance of
this codon variation was not investigated further. Allele
frequency in IDH2 is 2.22% in oral cancer and 3.23% in ALL.
Allele frequency of IDH1 is 3.23% in ALL and no mutation
hotspots are detectable in OSCC. Since the observed
nucleotide polymorphism is the transition of GGC to GGT,
both of which encode glycine, this base change is assum-
edly neutral.
The only silent mutation observed in the four AML
specimens was over pG313 (c.939A > G) of IDH2. The allele
frequency is 25% (two of eight). No nucleotide poly-
morphisms were identified in IDH1. However, this may have
been due to the limited numbers of specimens analyzed.
This synonymous change occurred in the same codon as that
observed in the ALL patients in this study. The biologic
implications are unclear. However, since the patients in
both groups were pediatric, the base change could be
an early indication of the oncogenesis of pediatric
malignancies.
Oral cancer is believed to result from multiple processes
involving many genetic alterations. The most common
cause is believed to be exposure to carcinogens associated
with chronic use of betel nuts, tobacco, and alcohol.
Although demographic and phenotypic presentations are
generally similar, responses to standard treatment vary
widely. Current therapies are not tailored to specificgenotypes. The discovery of novel gain-ofefunction IDH
mutations in GBM and AML in the current study has prom-
ising therapeutic considerations. However, further studies
are needed to identify associations among IDH, oral cancer,
and even ALL. To date, no IDH mutations of OSCC have been
reported. Possible explanations for the lack of R132C
mutations observed in this study are the very low incidence
of this mutation (reportedly 1.7%) and the small number of
samples screened in this study. In short, this study found
that HRM is a cost-effective method of mutation screening
and that IDH is not a reliable molecular marker of oral
cancer or ALL.Acknowledgment
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